{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:07Z","timestamp":1790758567817,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":178,"publisher":"Springer US","isbn-type":[{"value":"9781071656068","type":"print"},{"value":"9781071656075","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2027]]},"DOI":"10.1007\/978-1-0716-5607-5_12","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:45:32Z","timestamp":1790754332000},"page":"159-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurable Residual Disease"],"prefix":"10.1007","author":[{"given":"Prashant R.","family":"Tembhare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitaram","family":"Ghogale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"e390010","DOI":"10.1200\/EDBK_390010","volume":"43","author":"SE Dekker","year":"2023","unstructured":"Dekker SE, Rea D, Cayuela J-M, Arnhardt I, Leonard J, Heuser M (2023) Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book 43:e390010","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"06","key":"12_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1055\/s-0043-1772203","volume":"44","author":"PR Tembhare","year":"2023","unstructured":"Tembhare PR (2023) Monitoring measurable\/minimal residual disease in acute myeloid leukemia: multiparametric flow cytometry-based approach. Indian J Med Paediatr Oncol 44(06):554\u2013565","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"26","key":"12_CR3","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Br\u00fcggemann M, Orfao A (2015) Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125(26):3996\u20134009","journal-title":"Blood"},{"issue":"12","key":"12_CR4","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood 111(12):5477\u20135485","journal-title":"Blood"},{"issue":"12","key":"12_CR5","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"7","key":"12_CR6","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol 3(7):e170580","journal-title":"JAMA Oncol"},{"issue":"7","key":"12_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB (2017) Measurable residual disease testing in acute myeloid leukaemia. Leukemia 31(7):1482\u20131490","journal-title":"Leukemia"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.critrevonc.2018.11.010","volume":"133","author":"I Moors","year":"2019","unstructured":"Moors I, Vandepoele K, Philipp\u00e9 J, Deeren D, Selleslag D, Breems D et al (2019) Clinical implications of measurable residual disease in AML: review of current evidence. Crit Rev Oncol Hematol 133:142\u2013148","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"12_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"29","key":"12_CR10","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","volume":"30","author":"H Inaba","year":"2012","unstructured":"Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY et al (2012) Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 30(29):3625\u20133632","journal-title":"J Clin Oncol"},{"issue":"8","key":"12_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA et al (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group. Blood 120(8):1581\u20131588","journal-title":"Blood"},{"issue":"20","key":"12_CR12","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","volume":"4","author":"LE Brodersen","year":"2020","unstructured":"Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W et al (2020) Morphologic remission status is limited compared to \u0394N flow cytometry: a Children\u2019s Oncology Group AAML0531 report. Blood Ad 4(20):5050\u20135061","journal-title":"Blood Ad"},{"issue":"12","key":"12_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291","journal-title":"Blood"},{"issue":"2","key":"12_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/leu.2016.234","volume":"31","author":"CH Pui","year":"2017","unstructured":"Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C et al (2017) Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia 31(2):333\u2013339","journal-title":"Leukemia"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fonc.2020.00577","volume":"10","author":"PR Tembhare","year":"2020","unstructured":"Tembhare PR, Narula G, Khanka T, Ghogale S, Chatterjee G, Patkar NV et al (2020) Post-induction measurable residual disease using multicolor flow cytometry is strongly predictive of inferior clinical outcome in the real-life management of childhood T-cell acute lymphoblastic leukemia: a study of 256 patients. Front Oncol 10:577","journal-title":"Front Oncol"},{"issue":"29","key":"12_CR16","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","volume":"36","author":"SS Winter","year":"2018","unstructured":"Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z et al (2018) Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children\u2019s oncology group AALL0434 methotrexate randomization. J Clin Oncol 36(29):2926\u20132934","journal-title":"J Clin Oncol"},{"issue":"32","key":"12_CR17","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin 31(32):4123\u20134131","journal-title":"J Clin"},{"issue":"14","key":"12_CR18","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1182\/bloodadvances.2022009534","volume":"7","author":"SE Karol","year":"2023","unstructured":"Karol SE, Coustan-Smith E, Pounds S, Wang L, Inaba H, Ribeiro RC et al (2023) Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia. Blood Adv 7(14):3651\u20133657","journal-title":"Blood Adv"},{"issue":"22","key":"12_CR19","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","volume":"24","author":"C Langebrake","year":"2006","unstructured":"Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F et al (2006) Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin 24(22):3686\u20133692","journal-title":"J Clin"},{"issue":"8","key":"12_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","volume":"126","author":"MJ Borowitz","year":"2015","unstructured":"Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232. Blood 126(8):964\u2013971","journal-title":"Blood"},{"issue":"1","key":"12_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14523","volume":"177","author":"B Buldini","year":"2017","unstructured":"Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C et al (2017) Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol. Bri J Haematol 177(1):116\u2013126","journal-title":"Bri J Haematol"},{"issue":"8","key":"12_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.31","volume":"3","author":"XQ Weng","year":"2013","unstructured":"Weng XQ, Shen Y, Sheng Y, Chen B, Wang JH, Li JM et al (2013) Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood Cancer J 3(8):e133","journal-title":"Blood Cancer J"},{"issue":"3","key":"12_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cll.2021.03.017","volume":"41","author":"X Chen","year":"2021","unstructured":"Chen X, Cherian S (2021) Role of minimal residual disease testing in acute myeloid leukemia. Clin Lab Med 41(3):467\u2013483","journal-title":"Clin Lab Med"},{"issue":"6","key":"12_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11899-017-0428-4","volume":"12","author":"RS Vedula","year":"2017","unstructured":"Vedula RS, Lindsley RC (2017) Measurement of residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 12(6):574\u2013581","journal-title":"Curr Hematol Malig Rep"},{"issue":"15","key":"12_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"JM Ribera","year":"2014","unstructured":"Ribera JM, Oriol A, Morgades M, Montesinos P, Sarr\u00e0 J, Gonz\u00e1lez-Campos J et al (2014) Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin 32(15):1595\u20131604","journal-title":"J Clin"},{"issue":"6","key":"12_CR26","doi-asserted-by":"publisher","first-page":"e30295","DOI":"10.1002\/pbc.30295","volume":"70","author":"A Popov","year":"2023","unstructured":"Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T et al (2023) A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement. Pediat Blood Cancer 70(6):e30295","journal-title":"Pediat Blood Cancer"},{"issue":"12","key":"12_CR27","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD et al (2018) Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19(12):1668\u20131679","journal-title":"Lancet Oncol"},{"key":"12_CR28","doi-asserted-by":"crossref","unstructured":"Reiterov\u00e1 M, Kohlscheen S, Maglia O, Sala S, Schumich A, Maurer-Granofszky M et al (2025) Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach. Clin Chem Lab Med 63(7):1419\u20131426","DOI":"10.1515\/cclm-2024-1503"},{"issue":"17","key":"12_CR29","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1182\/blood.2024026381","volume":"145","author":"W Zhang","year":"2025","unstructured":"Zhang W, Cai J, Wang X, Ma Y, Zhu X, Yu J et al (2025) Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL. Blood 145(17):1890\u2013902","journal-title":"Blood"},{"issue":"4","key":"12_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.beha.2018.09.009","volume":"31","author":"FR Appelbaum","year":"2018","unstructured":"Appelbaum FR (2018) Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. Best Pract Res Clin Haematol 31(4):405\u2013409","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"12_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/17474086.2021.1967137","volume":"14","author":"F Ceppi","year":"2021","unstructured":"Ceppi F, Rizzati F, Colombini A, Conter V, Cazzaniga G (2021) Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia. Expert Rev Hematol 14(9):795\u2013807","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"12_CR32","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3109\/10428194.2016.1160085","volume":"57","author":"K Pettit","year":"2016","unstructured":"Pettit K, Stock W, Walter RB (2016) Incorporating measurable (\u2018minimal\u2019) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 57(7):1527\u20131533","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"12_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3324\/haematol.2008.003137","volume":"94","author":"CA Scrideli","year":"2009","unstructured":"Scrideli CA, Assump\u00e7\u00e3o JG, Ganazza MA, Ara\u00fajo M, Toledo SR, Lee ML et al (2009) A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 94(6):781\u2013789","journal-title":"Haematologica"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"614521","DOI":"10.3389\/fped.2020.614521","volume":"8","author":"N Vega-Garc\u00eda","year":"2020","unstructured":"Vega-Garc\u00eda N, Perez-Jaume S, Esperanza-Cebollada E, Vicente-Garc\u00e9s C, Torrebadell M, Jim\u00e9nez-Velasco A et al (2020) Measurable residual disease assessed by flow-cytometry is a stable prognostic factor for pediatric T-cell acute lymphoblastic leukemia in consecutive SEHOP protocols whereas the impact of oncogenetics depends on treatment. Front Pediatr 8:614521","journal-title":"Front Pediatr"},{"issue":"26","key":"12_CR35","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"1","key":"12_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00941-4","volume":"13","author":"D Xu","year":"2023","unstructured":"Xu D, Yang Y, Yin Z, Tu S, Nie D, Li Y et al (2023) Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study. Blood Cancer J 13(1):168","journal-title":"Blood Cancer J"},{"issue":"1","key":"12_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/PPO.0000000000000572","volume":"28","author":"G Gui","year":"2022","unstructured":"Gui G, Hourigan CS (2022) Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia. Cancer J 28(1):73\u201377","journal-title":"Cancer J"},{"key":"12_CR38","doi-asserted-by":"crossref","unstructured":"Meddi E, Savi A, Moretti F, Mallegni F, Palmieri R, Paterno G et al (2023) Measurable residual disease (MRD) as a surrogate efficacy-response biomarker in AML. Inte J MolSciences 24(4):3062","DOI":"10.3390\/ijms24043062"},{"key":"12_CR39","unstructured":"Health Quality Ontario. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser 2016;16(7):1\u201352. PMID: 27099643; PMCID: PMC4808716"},{"issue":"4-5","key":"12_CR40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0145-2126(81)90002-3","volume":"5","author":"KF Bradstock","year":"1981","unstructured":"Bradstock KF, Janossy G, Tidman N, Papageorgiou ES, Prentice HG, Willoughby M et al (1981) Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 5(4-5):301\u2013309","journal-title":"Leuk Res"},{"issue":"5","key":"12_CR41","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.4049\/jimmunol.135.5.3144","volume":"135","author":"JJ van Dongen","year":"1985","unstructured":"van Dongen JJ, Hooijkaas H, Comans-Bitter M, H\u00e4hlen K, de Klein A, van Zanen GE et al (1985) Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol 135(5):3144\u20133150","journal-title":"J Immunol"},{"issue":"5","key":"12_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","volume":"8","author":"BD Cheson","year":"1990","unstructured":"Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8(5):813\u2013819","journal-title":"J Clin Oncol"},{"issue":"3","key":"12_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0950-3536(09)90004-X","volume":"4","author":"A Hagenbeek","year":"1991","unstructured":"Hagenbeek A, Martens AC (1991) Minimal residual disease in acute leukaemia: preclinical studies in a relevant rat model (BNML). Baillieres Clin Haematol 4(3):609\u2013635","journal-title":"Baillieres Clin Haematol"},{"issue":"12","key":"12_CR44","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1007\/s00277-024-06008-z","volume":"103","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Lan J (2024) Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia. Ann Hematol 103(12):4869\u20134881","journal-title":"Ann Hematol"},{"issue":"1","key":"12_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12094-023-03251-0","volume":"26","author":"E Ramos Elbal","year":"2024","unstructured":"Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cort\u00e9s MB, Llinares ME et al (2024) Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Ooncol 26(1):278\u2013287","journal-title":"Clin Transl Ooncol"},{"issue":"12","key":"12_CR46","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L (2022) Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica 107(12):2783\u20132793","journal-title":"Haematologica"},{"issue":"6","key":"12_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11899-017-0419-5","volume":"12","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wood BL (2017) Methods of detection of measurable residual disease in AML. Curr Hhematol Malig Rep 12(6):557\u2013567","journal-title":"Curr Hhematol Malig Rep"},{"issue":"1","key":"12_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cyto.b.21831","volume":"98","author":"PR Tembhare","year":"2020","unstructured":"Tembhare PR, Subramanian Pg PG, Ghogale S, Chatterjee G, Patkar NV, Gupta A et al (2020) A high-sensitivity 10-color flow cytometric minimal residual disease assay in b-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients. . Cytometry B Clin Cytom 98(1):57\u201367","journal-title":". Cytometry B Clin Cytom"},{"issue":"4","key":"12_CR49","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cyto.b.21939","volume":"100","author":"PR Tembhare","year":"2021","unstructured":"Tembhare PR, Chatterjee G, Khanka T, Ghogale S, Badrinath Y, Deshpande N et al (2021) Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. Cytometry B Clin Cytom 100(4):421\u2013433","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"12_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ejh.14102","volume":"112","author":"G Chatterjee","year":"2024","unstructured":"Chatterjee G, Dhende P, Raj S, Shetty V, Ghogale S, Deshpande N et al (2024) 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia\/lymphoma: real-world applicability and challenges. Eur J Haematol 112(1):122\u2013136","journal-title":"Eur J Haematol"},{"issue":"9","key":"12_CR51","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A et al (2020) Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 135(9):680\u2013688","journal-title":"Blood"},{"issue":"10","key":"12_CR52","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","volume":"24","author":"DA Jacobsohn","year":"2018","unstructured":"Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR et al (2018) Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and wilms tumor 1 gene expression. Biol Bblood Marrow Transplant 24(10):2040\u20132046","journal-title":"Biol Bblood Marrow Transplant"},{"issue":"1","key":"12_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00951-2","volume":"13","author":"J \u00d3skarsson","year":"2023","unstructured":"\u00d3skarsson J, R\u00f6gnvaldsson S, Thorsteinsdottir S, Aspelund T, Gunnarsson SB, H\u00e1konard\u00f3ttir GK et al (2023) Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: proposal for a bone marrow quality index. Blood Cancer J 13(1):177","journal-title":"Blood Cancer J"},{"issue":"5","key":"12_CR54","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","volume":"35","author":"N Patkar","year":"2021","unstructured":"Patkar N, Kakirde C, Shaikh AF, Salve R, Bhanshe P, Chatterjee G et al (2021) Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia 35(5):1392\u20131404","journal-title":"Leukemia"},{"issue":"2","key":"12_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cyto.b.22043","volume":"102","author":"J Singh","year":"2022","unstructured":"Singh J, Gorniak M, Grigoriadis G, Westerman D, McBean M, Venn N et al (2022) Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia. Cytometry B Clin Cytom 102(2):115\u2013122","journal-title":"Cytometry B Clin Cytom"},{"key":"12_CR56","doi-asserted-by":"crossref","unstructured":"van der Linde R, Gatt PN, Smith S, Fernandez MA, Vaughan L, Blyth E et al (2023) Measurable residual disease (MRD) by flow cytometry in adult B-acute lymphoblastic leukaemia (B-ALL) and acute myeloid leukaemia (AML): correlation with molecular MRD testing and clinical outcome at one year. Cancers 15(20):5064","DOI":"10.3390\/cancers15205064"},{"issue":"12","key":"12_CR57","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3324\/haematol.2021.279777","volume":"107","author":"F Buccisano","year":"2022","unstructured":"Buccisano F, Palmieri R, Piciocchi A, Arena V, Maurillo L, Del Principe MI et al (2022) Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial. Haematologica 107(12):2823\u20132833","journal-title":"Haematologica"},{"issue":"8","key":"12_CR58","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-021-01126-3","volume":"35","author":"B Paiva","year":"2021","unstructured":"Paiva B, Vidriales MB, Sempere A, Tar\u00edn F, Colado E, Benavente C et al (2021) Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia 35(8):2358\u20132870","journal-title":"Leukemia"},{"issue":"6","key":"12_CR59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1055\/s-0043-1772203","volume":"44","author":"T PR","year":"2023","unstructured":"PR T (2023) Monitoring measurable\/minimal residual disease in acute myeloid leukemia: multiparametric flow cytometry-based approach. Ind J Med Paediatr Oncol 44(6):554\u2013565","journal-title":"Ind J Med Paediatr Oncol"},{"key":"12_CR60","doi-asserted-by":"crossref","unstructured":"Roshal M, Gao Q (2025) Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments. Am J Clin Pathol 163(5):775\u2013793","DOI":"10.1093\/ajcp\/aqae187"},{"issue":"6","key":"12_CR61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cyto.b.22144","volume":"104","author":"JM Tettero","year":"2023","unstructured":"Tettero JM, Dakappagari N, Heidinga ME, Oussoren-Brockhoff Y, Hanekamp D, Pahuja A et al (2023) Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry B Clin Cytom 104(6):426\u2013439","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"12_CR62","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W et al (2022) Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. HemaSphere 6(1):e676","journal-title":"HemaSphere"},{"key":"12_CR63","unstructured":"https:\/\/euroflow.org\/protocols\/"},{"issue":"3","key":"12_CR64","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2014.04.005","volume":"157","author":"SC Bendall","year":"2014","unstructured":"Bendall SC, Davis KL, Amir el AD, Tadmor MD, Simonds EF, Chen TJ et al (2014) Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development. Cell 157(3):714\u2013725","journal-title":"Cell"},{"issue":"1","key":"12_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cyto.b.21482","volume":"94","author":"S Cherian","year":"2018","unstructured":"Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL (2018) A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia\/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom 94(1):112\u2013120","journal-title":"Cytometry B Clin Cytom"},{"issue":"Suppl 1","key":"12_CR66","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1182\/blood-2024-206184","volume":"144","author":"D Nguyen","year":"2024","unstructured":"Nguyen D, Jabbour E, Jain N, Karrar O, Nasnas C, Haddad FG et al (2024) Clearance of very low levels of measurable residual disease with blinatumomab significantly improves outcomes in B-cell acute lymphoblastic leukemia. Blood 144(Suppl 1):1465","journal-title":"Blood"},{"issue":"1","key":"12_CR67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","volume":"3","author":"MA Pulsipher","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S et al (2022) Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov 3(1):66\u201381","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"12_CR68","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","volume":"104","author":"R Bassan","year":"2019","unstructured":"Bassan R, Br\u00fcggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S (2019) A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 104(10):2028\u20132039","journal-title":"Haematologica"},{"issue":"14","key":"12_CR69","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","volume":"129","author":"D Campana","year":"2017","unstructured":"Campana D, Pui CH (2017) Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 129(14):1913\u20131918","journal-title":"Blood"},{"issue":"4","key":"12_CR70","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41375-019-0599-1","volume":"34","author":"M Kotrova","year":"2020","unstructured":"Kotrova M, Volland A, Kehden B, Trautmann H, Ritgen M, W\u00e4sch R et al (2020) Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia 34(4):1154\u20131157","journal-title":"Leukemia"},{"issue":"23","key":"12_CR71","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","volume":"117","author":"E Coustan-Smith","year":"2011","unstructured":"Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117(23):6267\u20136276","journal-title":"Blood"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"112429","DOI":"10.1016\/j.jim.2018.03.005","volume":"475","author":"\u0141 S\u0119dek","year":"2019","unstructured":"S\u0119dek \u0141, Theunissen P, Sobral da Costa E, van der Sluijs-Gelling A, Mejstrikova E, Gaipa G et al (2019) Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods 475:112429","journal-title":"J Immunol Methods"},{"issue":"1","key":"12_CR73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cyto.b.21486","volume":"94","author":"PR Tembhare","year":"2018","unstructured":"Tembhare PR, Ghogale S, Ghatwai N, Badrinath Y, Kunder N, Patkar NV et al (2018) Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD assay. Cytom B Clin CCytom 94(1):100\u2013111","journal-title":"Cytom B Clin CCytom"},{"issue":"23","key":"12_CR74","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E et al (2010) Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 115(23):4657\u20134663","journal-title":"Blood"},{"issue":"3","key":"12_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M et al (2017) Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129(3):347\u2013357","journal-title":"Blood"},{"issue":"4","key":"12_CR76","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ijlh.14250","volume":"46","author":"N Das","year":"2024","unstructured":"Das N, Panda D, Gajendra S, Gupta R, Thakral D, Kaur G et al (2024) Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: deciphering the spectrum, complexity and immunophenotypic heterogeneity. Int J Lab Hematol 46(4):646\u2013656","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"12_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","volume":"9","author":"A Al-Mawali","year":"2016","unstructured":"Al-Mawali A, Gillis D, Lewis I (2016) Immunoprofiling of leukemic stem cells CD34+\/CD38-\/CD123+ delineate FLT3\/ITD-positive clones. J Hematol Oncol 9(1):61","journal-title":"J Hematol Oncol"},{"key":"12_CR78","doi-asserted-by":"publisher","first-page":"103710","DOI":"10.1016\/j.critrevonc.2022.103710","volume":"175","author":"SK Khaldoyanidi","year":"2022","unstructured":"Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M (2022) Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research. Crit Rev Oncol Hematol 175:103710","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"12_CR79","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1002\/cpcy.73","volume":"93","author":"BL Wood","year":"2020","unstructured":"Wood BL (2020) Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protoc Cytom 93(1):e73","journal-title":"Curr Protoc Cytom"},{"issue":"2","key":"12_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","volume":"31","author":"X Chen","year":"2017","unstructured":"Chen X, Wood BL (2017) Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev 31(2):63\u201375","journal-title":"Blood Rev"},{"issue":"1","key":"12_CR81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.21873\/anticanres.16145","volume":"43","author":"T Yoroidaka","year":"2023","unstructured":"Yoroidaka T, Yamashita T, Murata R, Yoshihara K, Yoshihara S, Ueda M et al (2023) Measurable residual disease assessment using next-generation flow in patients with relapsed and refractory multiple myeloma treated with a combination of carfilzomib, lenalidomide, and dexamethasone. Anticancer Re 43(1):157\u2013165","journal-title":"Anticancer Re"},{"issue":"Suppl 1","key":"12_CR82","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1182\/blood-2024-208387","volume":"144","author":"L Sedek","year":"2024","unstructured":"Sedek L, Soriano B, S\u0142ota \u0141, Br\u00fcggemann M, Lasia A, Kohlscheen S et al (2024) A novel 12-color 2-tube next generation flow approach enables sensitive detection of measurable residual disease in virtually all T-cell acute lymphoblastic leukemia patients. Blood 144(Suppl 1):4218","journal-title":"Blood"},{"issue":"4","key":"12_CR83","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/sj.leu.2403303","volume":"18","author":"MN Dworzak","year":"2004","unstructured":"Dworzak MN, Fr\u00f6schl G, Printz D, Zen LD, Gaipa G, Ratei R et al (2004) CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 18(4):703\u2013708","journal-title":"Leukemia"},{"issue":"3","key":"12_CR84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cyto.b.20511","volume":"78","author":"M Roshal","year":"2010","unstructured":"Roshal M, Fromm JR, Winter S, Dunsmore K, Wood BL (2010) Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytom B Clin Cytom 78(3):139\u2013146","journal-title":"Cytom B Clin Cytom"},{"issue":"10","key":"12_CR85","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/modpathol.2013.78","volume":"26","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Fan X, Routbort M, Cameron Yin C, Singh R, Bueso-Ramos C et al (2013) Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia\/lymphoma. Mod Pathol 26(10):1338\u20131345","journal-title":"Mod Pathol"},{"issue":"28","key":"12_CR86","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z et al (2020) Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed t-cell acute lymphoblastic leukemia. J Clin Oncol 38(28):3282\u20133293","journal-title":"J Clin Oncol"},{"issue":"1","key":"12_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06033-1","volume":"23","author":"N Das","year":"2022","unstructured":"Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R et al (2022) Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials 23(1):102","journal-title":"Trials"},{"issue":"1","key":"12_CR88","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<48::AID-MPO9>3.0.CO;2-T","volume":"28","author":"Z Aziz","year":"1997","unstructured":"Aziz Z, Zahid M, Mahmood R, Maqbool S (1997) Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis. Med Pediatr Oncol 28(1):48\u201353","journal-title":"Med Pediatr Oncol"},{"issue":"6","key":"12_CR89","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","volume":"14","author":"N G\u00f6kbuget","year":"2000","unstructured":"G\u00f6kbuget N, Hoelzer D, Arnold R, B\u00f6hme A, Bartram CR, Freund M et al (2000) Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin N Am 14(6):1307\u201325. ix","journal-title":"Hematol Oncol Clin N Am"},{"issue":"4","key":"12_CR90","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1182\/bloodadvances.2021005624","volume":"6","author":"AW Rijneveld","year":"2022","unstructured":"Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE et al (2022) Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Adv 6(4):1115\u20131125","journal-title":"Blood Adv"},{"issue":"3","key":"12_CR91","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey DT, O\u2019Connor D (2020) How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 135(3):159\u2013166","journal-title":"Blood"},{"issue":"1","key":"12_CR92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2006.06.8312","volume":"25","author":"JM Ribera","year":"2007","unstructured":"Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, P\u00e9rez-Hurtado JM et al (2007) Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 25(1):16\u201324","journal-title":"J Clin Oncol"},{"issue":"24","key":"12_CR93","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","volume":"36","author":"F Huguet","year":"2018","unstructured":"Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M et al (2018) Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol 36(24):2514\u20132523","journal-title":"J Clin Oncol"},{"issue":"5","key":"12_CR94","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA et al (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873","journal-title":"Haematologica"},{"issue":"23","key":"12_CR95","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD (2014) Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?. Blood 124(23):3345\u20133355","journal-title":"Blood"},{"issue":"10","key":"12_CR96","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/17460441.2017.1356818","volume":"12","author":"\u00d8 Bruserud","year":"2017","unstructured":"Bruserud \u00d8, Aaseb\u00f8 E, Hernandez-Valladares M, Tsykunova G, Reikvam H (2017) Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opin Drug Discov 12(10):1053\u20131065","journal-title":"Expert Opin Drug Discov"},{"key":"12_CR97","doi-asserted-by":"crossref","unstructured":"Cloos J, Harris JR, Janssen J, Kelder A, Huang F, Sijm G, et al (2018) Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J Vis Exp. (133):56386","DOI":"10.3791\/56386-v"},{"issue":"6","key":"12_CR98","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1586\/17474086.2014.959921","volume":"7","author":"R Wouters","year":"2014","unstructured":"Wouters R, Cucchi D, Kaspers GJ, Schuurhuis GJ, Cloos J (2014) Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Exp Rev Hematol 7(6):791\u2013805","journal-title":"Exp Rev Hematol"},{"issue":"1","key":"12_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06760-1","volume":"20","author":"SK Heo","year":"2020","unstructured":"Heo SK, Noh EK, Ju LJ, Sung JY, Jeong YK, Cheon J et al (2020) CD45(dim)CD34(+)CD38(-)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia. BMC Cancer 20(1):285","journal-title":"BMC Cancer"},{"key":"12_CR100","doi-asserted-by":"crossref","unstructured":"Wijnands C, Noori S, Donk N, VanDuijn MM, Jacobs JFM (2023) Advances in minimal residual disease monitoring in multiple myeloma. Crit Rev Clin Lab Sci 60(7):518\u2013534","DOI":"10.1080\/10408363.2023.2209652"},{"issue":"1","key":"12_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00803-z","volume":"13","author":"S Noori","year":"2023","unstructured":"Noori S, Wijnands C, Langerhorst P, Bonifay V, Stingl C, Touzeau C et al (2023) Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J 13(1):30","journal-title":"Blood Cancer J"},{"issue":"4","key":"12_CR102","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T et al (2022) Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 139(4):492\u2013501","journal-title":"Blood"},{"issue":"9","key":"12_CR103","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","volume":"8","author":"BA Derman","year":"2022","unstructured":"Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson JrLD et al (2022) Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol 8(9):1278\u20131286","journal-title":"JAMA Oncol"},{"issue":"25","key":"12_CR104","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A et al (2022) Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol 40(25):2889\u20132900","journal-title":"J Clin Oncol"},{"issue":"25","key":"12_CR105","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN et al (2022) Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 40(25):2901\u20132912","journal-title":"J Clin Oncol"},{"issue":"6","key":"12_CR106","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H et al (2022) Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 139(6):835\u2013844","journal-title":"Blood"},{"issue":"1","key":"12_CR107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/hematology.2021000230","volume":"2021","author":"AJ Yee","year":"2021","unstructured":"Yee AJ, Raje N (2021) Minimal residual disease in multiple myeloma: why, when, where. Hematology Am Soc Hematol Educ Program 2021(1):37\u201345","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"12_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva S, Bruinink DHO, Rihova L, D\u2019Agostino M, Pantani L, Capra A et al (2021) Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J 11(6):106","journal-title":"Blood Cancer J"},{"issue":"2","key":"12_CR109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cyto.b.21862","volume":"98","author":"KT Soh","year":"2020","unstructured":"Soh KT, Tario Jr.JD, Hahn TE, Hillengass J, McCarthy PL, Wallace PK (2020) Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Cytometry B Clin Cytom 98(2):161\u2013173","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"12_CR110","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB et al (2020) Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 38(8):784\u2013792","journal-title":"J Clin Oncol"},{"issue":"14","key":"12_CR111","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","volume":"4","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y et al (2020) Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv 4(14):3295\u20133301","journal-title":"Blood Adv"},{"issue":"1","key":"12_CR112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A et al (2017) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 3(1):28\u201335","journal-title":"JAMA Oncol"},{"issue":"23","key":"12_CR113","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4(23):5988\u20135999","journal-title":"Blood Adv"},{"issue":"7","key":"12_CR114","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat R, Anderson K, Munshi N (2024) Role of minimal residual disease assessment in multiple myeloma. Haematologica 109(7):2049\u20132059","journal-title":"Haematologica"},{"key":"12_CR115","doi-asserted-by":"crossref","unstructured":"Tzasta A, Wijnands C, Baalman K, van Gool AJ, Zweegman S, Jacobs JFM (2015) Advances in multiple myeloma blood-based monitoring and its clinical applications. Crit Rev Clin Lab Sci 62(7):491\u2013509","DOI":"10.1080\/10408363.2025.2512466"},{"issue":"6","key":"12_CR116","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","volume":"22","author":"B Paiva","year":"2025","unstructured":"Paiva B, Shi Q, Puig N, Cedena MT, Orfao A, Durie BGM et al (2025) Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nature Rev Clin Oncol 22(6):424\u2013438","journal-title":"Nature Rev Clin Oncol"},{"issue":"8","key":"12_CR117","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e46.","journal-title":"Lancet Oncol"},{"issue":"1","key":"12_CR118","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12672-024-00938-w","volume":"15","author":"M Zhou","year":"2024","unstructured":"Zhou M, Chen Y, Gong Y, Zhu M, Cen J, Pan J et al (2024) Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discover Oncol 15(1):78","journal-title":"Discover Oncol"},{"key":"12_CR119","doi-asserted-by":"crossref","unstructured":"Yoroidaka T, Takamatsu H, Urushihara R, Itagaki M, Yoshihara S, Sato K et al (2025) Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study. Haematologica 110(9):2160\u20132170","DOI":"10.3324\/haematol.2025.287411"},{"issue":"10","key":"12_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M et al (2020) Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 10(10):108","journal-title":"Blood Cancer J"},{"issue":"6","key":"12_CR121","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cyto.b.22099","volume":"102","author":"H Sriram","year":"2022","unstructured":"Sriram H, Kunjachan F, Khanka T, Gawai S, Ghogale S, Deshpande N et al (2022) Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. Cytometry B Clin Cytom 102(6):462\u2013470","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"12_CR122","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12288-017-0822-z","volume":"33","author":"G Chatterjee","year":"2017","unstructured":"Chatterjee G, Gujral S, Subramanian PG, Tembhare PR (2017) Clinical relevance of multicolour flow cytometry in plasma cell disorders. Indian J Hematol Blood Transfus 33(3):303\u2013315","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"12_CR123","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cyto.b.21619","volume":"94","author":"PR Tembhare","year":"2018","unstructured":"Tembhare PR, Ghogale S, Tauro W, Badrinath Y, Deshpande N, Kedia S et al (2018) Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry B Clin Cytom 94(3):509\u2013519","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"12_CR124","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cyto.b.22053","volume":"102","author":"KT Soh","year":"2022","unstructured":"Soh KT, Came N, Otteson GE, Jevremovic D, Shi M, Olteanu H et al (2022) Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis. Cytom B Clin Cytom 102(2):88\u2013106","journal-title":"Cytom B Clin Cytom"},{"key":"12_CR125","doi-asserted-by":"crossref","unstructured":"Puig N, Flores-Montero J, Burgos L, Cedena MT, Cord\u00f3n L, P\u00e9rez JJ et al (2021) Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma. Cancers 213(19):4924","DOI":"10.3390\/cancers13194924"},{"issue":"4","key":"12_CR126","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1002\/hem3.63","volume":"8","author":"PR Tembhare","year":"2024","unstructured":"Tembhare PR, Sriram H, Khanka T, Gawai S, Bagal B, Ghogale SG et al (2024) Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant. HemaSphere 8(4):e63","journal-title":"HemaSphere"},{"issue":"4","key":"12_CR127","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.24.01192","volume":"43","author":"F Simon","year":"2025","unstructured":"Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, F\u00fcrstenau M et al (2025) End point surrogacy in first-line chronic lymphocytic leukemia. J Clin Oncol 43(4):381\u201391.","journal-title":"J Clin Oncol"},{"key":"12_CR128","doi-asserted-by":"crossref","unstructured":"Greenberg MR, Lucido T, Singh K, Rhodes JM (2025) The impact of minimal residual disease measurement in the management of chronic lymphocytic leukemia. Cancers 17(10):1708","DOI":"10.3390\/cancers17101708"},{"issue":"9","key":"12_CR129","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","volume":"10","author":"FA Rios-Olais","year":"2024","unstructured":"Rios-Olais FA, McGary AK, Tsang M, Almader-Douglas D, Leis JF, Buras MR et al (2024) Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis. JAMA Oncol 10(9):1221\u20131227","journal-title":"JAMA Oncol"},{"issue":"4","key":"12_CR130","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A et al (2024) Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med 390(4):326\u2013337","journal-title":"N Engl J Med"},{"issue":"8","key":"12_CR131","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s11864-023-01103-1","volume":"24","author":"FA Rios-Olais","year":"2023","unstructured":"Rios-Olais FA, Hilal T (2023) Measurable residual disease in chronic lymphocytic leukemia: current understanding and evolving role in clinical practice. Curr Treat Option On 24(8):907\u2013928","journal-title":"Curr Treat Option On"},{"key":"12_CR132","doi-asserted-by":"publisher","first-page":"1130617","DOI":"10.3389\/fonc.2023.1130617","volume":"13","author":"A Fisher","year":"2023","unstructured":"Fisher A, Goradia H, Martinez-Calle N, Patten P, Munir T (2023) The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. Front Oncol 13:1130617","journal-title":"Front Oncol"},{"issue":"34","key":"12_CR133","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A et al (2021) Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 39(34):3853\u20133865","journal-title":"J Clin Oncol"},{"issue":"4","key":"12_CR134","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3960\/jslrt.20014","volume":"60","author":"T Uchiyama","year":"2020","unstructured":"Uchiyama T, Yokoyama A, Aoki S (2020) Measurable residual disease in the treatment of chronic lymphocytic leukemia. J Clin Exp Hematopathol 60(4):138\u2013145","journal-title":"J Clin Exp Hematopathol"},{"issue":"4","key":"12_CR135","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C et al (2019) Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol 37(4):269\u2013277","journal-title":"J Clin Oncol"},{"issue":"6","key":"12_CR136","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41375-018-0109-x","volume":"32","author":"P Ghia","year":"2018","unstructured":"Ghia P, Rawstron A (2018) Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia 32(6):1307\u20131316","journal-title":"Leukemia"},{"issue":"6","key":"12_CR137","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","volume":"23","author":"AP Kater","year":"2022","unstructured":"Kater AP, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ et al (2022) Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 23(6):818\u2013828","journal-title":"Lancet Oncol"},{"issue":"4","key":"12_CR138","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J et al (2016) A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 30(4):929\u2013936","journal-title":"Leukemia"},{"key":"12_CR139","doi-asserted-by":"crossref","unstructured":"Rawstron A (2025) Measurable\/minimal residual disease: what method and what cut-off? Hematol Oncol Clin N Am 39(5):917\u2013934","DOI":"10.1016\/j.hoc.2025.05.012"},{"issue":"8","key":"12_CR140","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM et al (2017) Ibrutinib treatment improves T cell number and function in CLL patients.  J Clin Investig 127(8):3052\u20133064","journal-title":"J Clin Investig"},{"key":"12_CR141","doi-asserted-by":"publisher","first-page":"103348","DOI":"10.1016\/j.eclinm.2025.103348","volume":"86","author":"NS Chandhok","year":"2025","unstructured":"Chandhok NS, Sekeres MA (2025) Measurable residual disease in hematologic malignancies: a biomarker in search of a standard. EClinicalMedicine 86:103348","journal-title":"EClinicalMedicine"},{"key":"12_CR142","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fonc.2019.00528","volume":"9","author":"S Galimberti","year":"2019","unstructured":"Galimberti S, Genuardi E, Mazziotta F, Iovino L, Morabito F, Grassi S et al (2019) The minimal residual disease in non-Hodgkin\u2019s lymphomas: from the laboratory to the clinical practice. Front Oncol 9:528","journal-title":"Front Oncol"},{"issue":"2","key":"12_CR143","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.14996","volume":"180","author":"ML Chase","year":"2018","unstructured":"Chase ML, Armand P (2018) Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol 180(2):177\u2013188","journal-title":"Br J Haematol"},{"issue":"5","key":"12_CR144","first-page":"550","volume":"42","author":"C Pott","year":"2024","unstructured":"Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M et al (2024) Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM Study.  Clin Oncol 42(5):550\u2013561","journal-title":"Clin Oncol"},{"issue":"12","key":"12_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00760-z","volume":"12","author":"F Ravandi","year":"2022","unstructured":"Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC et al (2022) Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer Jl 12(12):165","journal-title":"Blood Cancer Jl"},{"issue":"4","key":"12_CR146","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3324\/haematol.2023.282898","volume":"109","author":"ZD Epstein-Peterson","year":"2024","unstructured":"Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A et al (2024) Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica 109(4):1149\u20131162","journal-title":"Haematologica"},{"issue":"3","key":"12_CR147","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A et al (2016) Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 101(3):336\u2013345","journal-title":"Haematologica"},{"issue":"2","key":"12_CR148","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cytob.21210","volume":"88","author":"J Chovancov\u00e1","year":"2015","unstructured":"Chovancov\u00e1 J, Bernard T, Stehl\u00edkov\u00e1 O, \u0160\u00e1lek D, Jan\u00edkov\u00e1 A, Mayer J et al (2015) Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach. Cytometry Clin Cytom 88(2):92\u2013100","journal-title":"Cytometry Clin Cytom"},{"issue":"4","key":"12_CR149","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cyto.b.21833","volume":"96","author":"JA DiGiuseppe","year":"2019","unstructured":"DiGiuseppe JA, Wood BL (2019) Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of b and t lymphoblastic leukemia\/lymphoma. Cytometry B Clin Cytom 96(4):256\u2013265","journal-title":"Cytometry B Clin Cytom"},{"key":"12_CR150","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","volume":"999","author":"BL Wood","year":"2013","unstructured":"Wood BL (2013) Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 999:123\u2013136","journal-title":"Methods Mol Biol"},{"issue":"3","key":"12_CR151","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cyto.b.21754","volume":"96","author":"SD Scott","year":"2019","unstructured":"Scott SD, Fletcher M, Whitehouse H, Whitby L, Yuan C, Mazzucchelli S et al (2019) Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?. Cytometry B, Clin Cytom 96(3):201\u2013208","journal-title":"Cytometry B, Clin Cytom"},{"issue":"6","key":"12_CR152","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/MPH.0b013e3181a1c0e8","volume":"31","author":"E Bj\u00f6rklund","year":"2009","unstructured":"Bj\u00f6rklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S et al (2009) Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol 31(6):406\u2013415","journal-title":"J Pediatr Hematol Oncol"},{"key":"12_CR153","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-1-4939-9650-6_14","volume":"2032","author":"B Greig","year":"2019","unstructured":"Greig B (2019) Quality control of immunophenotyping. Methods Mol Biol 2032:227\u2013279","journal-title":"Methods Mol Biol"},{"key":"12_CR154","doi-asserted-by":"crossref","unstructured":"Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E et al (2021) An extensive quality control and quality assurance (QC\/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: an I-BFM-FLOW-network report. Cancers 13(23):6148","DOI":"10.3390\/cancers13236148"},{"key":"12_CR155","doi-asserted-by":"crossref","unstructured":"Bras AE, Matarraz S, Nierkens S, Fern\u00e1ndez P, Philipp\u00e9 J, Aanei CM et al (2022) Quality assessment of a large multi-center flow cytometric dataset of acute myeloid leukemia patients-a euroflow study. Cancers;14(8):2011","DOI":"10.3390\/cancers14082011"},{"issue":"2","key":"12_CR156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cyto.a.22581","volume":"87","author":"T Kalina","year":"2015","unstructured":"Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VH, Novakova M et al (2015) Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 87(2):145\u2013156","journal-title":"Cytometry A"},{"issue":"9","key":"12_CR157","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26(9):1986\u20132010","journal-title":"Leukemia"},{"issue":"4","key":"12_CR158","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cyto.a.24686","volume":"103","author":"J Hoffmann","year":"2023","unstructured":"Hoffmann J, Thrun MC, R\u00f6hnert MA, von Bonin M, Oelschl\u00e4gel U, Neubauer A et al (2023) Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: the Cinderella method. Cytometry A 103(4):304\u2013312","journal-title":"Cytometry A"},{"issue":"3","key":"12_CR159","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","volume":"38","author":"JM Tettero","year":"2024","unstructured":"Tettero JM, Heidinga ME, Mocking TR, Fransen G, Kelder A, Scholten WJ et al (2024) Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia. Leukemia 38(3):630\u2013639","journal-title":"Leukemia"},{"key":"12_CR160","doi-asserted-by":"publisher","first-page":"1001048","DOI":"10.3389\/fonc.2022.1001048","volume":"12","author":"I Vigliotta","year":"2022","unstructured":"Vigliotta I, Armuzzi S, Barone M, Solli V, Pistis I, Borsi E et al (2022) The ALLgorithMM: how to define the hemodilution of bone marrow samples in lymphoproliferative diseases. Front Oncol 12:1001048","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"12_CR161","first-page":"S49","volume":"29","author":"DA Armbruster","year":"2008","unstructured":"Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Re 29(Suppl 1):S49\u201352","journal-title":"Clin Biochem Re"},{"key":"12_CR162","unstructured":"https:\/\/www.cytometry.org\/web\/modules\/Module_25.pdf"},{"key":"12_CR163","unstructured":"Clinical and Laboratory Standards Institute (2004). Protocols for determination of limits of detection and limits of quantitation AGW, PA USA: CLSI; CLSI document EP17"},{"issue":"6","key":"12_CR164","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cyto.b.20430","volume":"74","author":"MN Dworzak","year":"2008","unstructured":"Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O et al (2008) Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom 74(6):331\u2013340","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"12_CR165","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A et al (2016) Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom 90(1):31\u201339","journal-title":"Cytometry B Clin Cytom"},{"key":"12_CR166","doi-asserted-by":"publisher","first-page":"746951","DOI":"10.3389\/fonc.2021.746951","volume":"11","author":"CM Aanei","year":"2021","unstructured":"Aanei CM, Veyrat-Masson R, Selicean C, Marian M, Rigollet L, Trifa AP et al (2021) Database-guided analysis for immunophenotypic diagnosis and follow-up of acute myeloid leukemia with recurrent genetic abnormalities. Front Oncol 11:746951","journal-title":"Front Oncol"},{"key":"12_CR167","doi-asserted-by":"crossref","unstructured":"Pi\u00f1ero P, Morillas M, Gutierrez N, Barrag\u00e1n E, Such E, Bre\u00f1a J et al (2022) Identification of leukemia-associated immunophenotypes by databaseguided flow cytometry provides a highly sensitive and reproducible strategy for the study of measurable residual disease in acute myeloblastic leukemia. Cancers 14(16):4010","DOI":"10.3390\/cancers14164010"},{"issue":"9","key":"12_CR168","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cyto.a.23852","volume":"95","author":"M Reiter","year":"2019","unstructured":"Reiter M, Diem M, Schumich A, Maurer-Granofszky M, Karawajew L, Rossi JG et al (2019) Automated flow cytometric MRD assessment in childhood acute B- Lymphoblastic leukemia using supervised machine learning. Cytometry A 95(9):966\u2013975","journal-title":"Cytometry A"},{"key":"12_CR169","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.compbiomed.2022.105314","volume":"144","author":"M W\u00f6dlinger","year":"2022","unstructured":"W\u00f6dlinger M, Reiter M, Weijler L, Maurer-Granofszky M, Schumich A, Sajaroff EO et al (2022) Automated identification of cell populations in flow cytometry data with transformers. Comput Biol Med 144:105314","journal-title":"Comput Biol Med"},{"issue":"4","key":"12_CR170","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/cyto.b.22143","volume":"106","author":"MWC Verbeek","year":"2024","unstructured":"Verbeek MWC, Rodr\u00edguez BS, Sedek L, Laqua A, Buracchi C, Buysse M et al (2024) Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: a EuroFlow study. Cytometry PB Clin Cytom 106(4):252\u2013263","journal-title":"Cytometry PB Clin Cytom"},{"issue":"4","key":"12_CR171","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.18802","volume":"202","author":"PC Nguyen","year":"2023","unstructured":"Nguyen PC, Nguyen V, Baldwin K, Kankanige Y, Blombery P, Came N et al (2023) Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia. Br J Haematol 202(4):760\u2013770","journal-title":"Br J Haematol"},{"issue":"2","key":"12_CR172","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/CCO.0000000000000607","volume":"32","author":"C Duetz","year":"2020","unstructured":"Duetz C, Bachas C, Westers TM, van de Loosdrecht AA (2020) Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?. Curr Opin Oncol 32(2):162\u2013169","journal-title":"Curr Opin Oncol"},{"key":"12_CR173","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ebiom.2018.10.042","volume":"37","author":"BS Ko","year":"2018","unstructured":"Ko BS, Wang YF, Li JL, Li CC, Weng PF, Hsu SC et al (2018) Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine. 37:91\u2013100","journal-title":"EBioMedicine."},{"issue":"5","key":"12_CR174","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/cyto.b.22084","volume":"102","author":"KE Shopsowitz","year":"2022","unstructured":"Shopsowitz KE, Liu L, Setiadi A, Al-Bakri M, Vercauteren S (2022) Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis. Cytometry B Clin Cytom 102(5):342\u2013352","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"12_CR175","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/cyto.a.24667","volume":"101","author":"KT Soh","year":"2022","unstructured":"Soh KT, Conway A, Liu X, Wallace PK (2022) Development of a 27-color panel for the detection of measurable residual disease in patients diagnosed with acute myeloid leukemia. Cytometry A 101(11):970\u2013983","journal-title":"Cytometry A"},{"key":"12_CR176","doi-asserted-by":"crossref","unstructured":"Maag AH, Swanton H, Kull M, Vegi NM, Feuring M (2023) Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). Cytometry A 103(7):551\u20139562","DOI":"10.1002\/cyto.a.24716"},{"issue":"3","key":"12_CR177","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/cyto.a.24811","volume":"105","author":"H Fokken","year":"2024","unstructured":"Fokken H, Waclawski J, Kattre N, Kloos A, M\u00fcller S, Ettinger M et al (2024) A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. Cytometry A 105(3):181\u2013195","journal-title":"Cytometry A"},{"key":"12_CR178","doi-asserted-by":"crossref","unstructured":"Matthes T (2024) Phenotypic analysis of hematopoietic stem and progenitor cell populations in acute myeloid leukemia based on spectral flow cytometry, a 20-color panel, and unsupervised learning algorithms. Int J Mol Sci 25(5):2847","DOI":"10.3390\/ijms25052847"}],"container-title":["Methods in Molecular Biology","Immunophenotyping"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5607-5_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:02:45Z","timestamp":1790755365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5607-5_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"ISBN":["9781071656068","9781071656075"],"references-count":178,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5607-5_12","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}